期刊
LANCET ONCOLOGY
卷 13, 期 1, 页码 E11-E22出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/S1470-2045(11)70175-9
关键词
-
类别
资金
- American Association for the Study of Liver Disease (AASLD)
- American Society of Transplant Surgeons (ASTS)
- European Association for the Study of the Liver (EASL)
- European-African Hepato-Pancreato-Biliary Association (E-AHPBA)
- European Liver and Intestine Transplant Association (ELITA)
- International Hepato-Pancreato-Biliary Association (IHPBA)
- International Liver Cancer Association (ILCA)
- International Liver Transplantation Society (ILTS)
- Transplantation Society (TTS)
- Bayer HealthCare
- Novartis
- Astellas
- Johnson Johnson
- Roche
- MSD
- AstraZeneca
- Nycomed
- B Braun
- Baxter
- MeVis
- CAScination
- Microsulis Medical
- University of Zurich
- Liver and Gastro-Intestinal Foundation
Although liver transplantation is a widely accepted treatment for hepatocellular carcinoma (HCC), much controversy remains and there is no generally accepted set of guidelines. An international consensus conference was held on Dec 2-4, 2010, in Zurich, Switzerland, with the aim of reviewing current practice regarding liver transplantation in patients with HCC and to develop internationally accepted statements and guidelines. The format of the conference was based on the Danish model. 19 working groups of experts prepared evidence-based reviews according to the Oxford classification, and drafted recommendations answering 19 specific questions. An independent jury of nine members was appointed to review these submissions and make final recommendations, after debates with the experts and audience at the conference. This report presents the final 37 statements and recommendations, covering assessment of candidates for liver transplantation, criteria for listing in cirrhotic and non-cirrhotic patients, role of tumour downstaging, management of patients on the waiting list, role of living donation, and post-transplant management.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据